| Metric | Q3-26 | Q3-25 |
|---|---|---|
| Revenue | 0.00 | 0.00 |
| Net Income | -3.87 | -2.30 |
| Diluted EPS | -0.31 | -0.19 |
- Net Income YoY
- -68.3%
Key highlights
- Net loss widened to $3.87 million in Q3 2026 from $2.30 million in the prior year period
- Revenue remained at $0.00 for the quarter as the company discontinued its clinical programs
- Diluted earnings per share decreased to -$0.31 compared to -$0.19 in Q3 2025
- Cash and cash equivalents totaled $11.6 million as of September 30, 2026
- Restructuring and transaction-related charges were the primary drivers of the quarterly deficit
How the Period Went
Synlogic, Inc. reported a zero-revenue quarter for the period ended September 30, 2026, consistent with the same period in 2025. The company’s net loss widened to $3.87 million, compared to a $2.30 million loss in the prior year. This represents a 68.3% increase in the net loss during the transition period. Diluted earnings per share also moved further into negative territory, reaching -$0.31 compared to -$0.19 in the third quarter of 2025. These figures highlight a period of increased spending despite the lack of commercial operations, driven by the company's significant structural shift.
Margins and Profitability
The widening net loss was largely a result of non-recurring expenses associated with the company’s strategic reorganization. Specifically, restructuring charges and transaction-related costs pushed the net loss to $3.87 million. As Synlogic has moved away from active research, the absence of revenue means that all operational and administrative outlays contribute directly to the bottom-line deficit. The company’s focus has shifted from clinical development to managing the financial obligations of its wind-down and the legal complexities of its pending merger with Caldera Therapeutics, which has created a temporary spike in professional services expenses.
Business Overview
Synlogic, Inc. is a biotechnology firm that historically specialized in Synthetic Biotic medicines, which are genetically engineered microbes designed to treat metabolic disorders. Following a comprehensive strategic review, the company has moved to discontinue all clinical trials and reduce its workforce. Currently, Synlogic’s primary business activity involves the execution of a merger agreement with Caldera Therapeutics, Inc. This strategic pivot is intended to preserve remaining capital and explore alternative paths for the company's asset base and technological platform within a combined corporate entity.
Financial Context
Synlogic’s financial position is defined by its transition toward a strategic exit. The $3.87 million net loss in the third quarter of 2026 reflects a widening deficit compared to the $2.30 million loss recorded in the same period last year. With no revenue generated during either period, the company’s burn rate is currently focused on fulfilling obligations related to its discontinued operations and upcoming merger. The ending cash and cash equivalents balance of $11.6 million provides a finite runway to finalize the transaction with Caldera Therapeutics, signaling the conclusion of Synlogic's independent research phase.
Industry Landscape
The biotechnology sector is currently characterized by heightened consolidation as development-stage firms navigate challenging funding environments and clinical hurdles. Synlogic’s decision to halt its programs and seek a merger aligns with broader industry trends where small-cap biotech companies prioritize cash preservation over high-risk research. By terminating its clinical pipeline, Synlogic has joined a cohort of biotech entities prioritizing strategic combinations. This environment favors companies with remaining liquidity, like Synlogic’s $11.6 million, which can be leveraged to facilitate corporate combinations in a tightening financial landscape for pre-revenue entities.
SEC filing by Synlogic, Inc. announcing its third quarter 2026 financial results.
Track SYNLOGIC, INC. live
Get the next SYNLOGIC, INC. SEC filing seconds after it lands.



